Telangiectases in scleroderma: A potential clinical marker of pulmonary arterial hypertension

Journal of Rheumatology

Volumn 37, Issue 1, 2010, Pages 98-104

  Shah, Ami A ^a   Wigley, Fredrick M ^a   Hummers, Laura K ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Pulmonary hypertension; Systemic sclerosis; Telangiectases

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AUTOANTIBODY; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN;

ADULT; AGE DISTRIBUTION; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE MARKER; FEMALE; HEART CATHETERIZATION; HEART RIGHT VENTRICLE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; RACE DIFFERENCE; SCLERODERMA; SCORING SYSTEM; SMOKING; SYSTOLIC BLOOD PRESSURE; TELANGIECTASIA;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MIDDLE AGED; PULMONARY ARTERY; SCLERODERMA, SYSTEMIC; TELANGIECTASIS;

EID: 73649099833     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090697     Document Type: Article

References (19)

1. Braverman IM, Ken-Yen A. Ultrastructure and three-dimensional reconstruction of several macular and papular telangiectases. J Invest Dermatol 1983;81:489-97.
2. Walker JG, Stirling J, Beroukas D, Dharmapatni K, Haynes DR, Smith MD, et al. Histopathological and ultrastructural features of dermal telangiectasias in systemic sclerosis. Pathology 2005;37:220-5.
3. Wigley FM. Vascular disease in scleroderma. Clin Rev Allergy Immunol 2009;36:150-75.
4. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
5. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
6. Mukerjee D, St. George D, Knight C, Davar J, Wells AU, Du Bois RM, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 2004;43:461-6.
7. Joglekar A, Tsai FS, McCloskey DA, Wilson JE, Seibold JR, Riley DJ. Bosentan in pulmonary arterial hypertension secondary to scleroderma. J Rheumatol 2006;33:61-8.
8. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-87.
9. Knudson RJ, Kaltenborn WT, Knudson DE, Burrows B. The single-breath carbon monoxide diffusing capacity. Reference equations derived from a healthy nonsmoking population and effects of hematocrit. Am Rev Respir Dis 1987;135:805-11.
10. Robert-Thomson PJ, Mould TL, Walker JG, Smith MD, Ahern MJ. Clinical utility of telangiectasia of hands in scleroderma and other rheumatic disorders. Asian Pac J Allergy Immunol 2002;20:7-12.
11. Kazandjian S, Bruneval P, Fiessinger JN, Camilleri JP, Housset E. Active proliferation of telangiectases in skin of patients with progressive systemic sclerosis (PSS). Arch Dermatol Res 1986;279:8-11.
12. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000;91:66-7.
13. Mould TL, Roberts-Thomson PJ. Pathogenesis of telangiectasia in scleroderma. Asian Pac J Allergy Immunol 2000;18:195-200.
14. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;8:345-51.
15. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996;13:189-95.
16. Fujimoto M, Hasegawa M, Hamaguchi Y, Komura K, Matsushita T, Yanaba K, et al. A clue for telangiectasis in systemic sclerosis: elevated serum soluble endoglin levels in patients with the limited cutaneous form of the disease. Dermatology 2006;213:88-92.
17. Wipff J, Kahan A, Hachulla E, Sibilia J, Cabane J, Meyer O, et al. Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. Rheumatology 2007;46:622-5.
18. Wipff J, Avouac J, Borderie D, Zerkak D, Lemarechal H, Kahan A, et al. Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology 2008;47:972-5.
19. Dharmapatni AA, Smith MD, Ahern MJ, Simpson A, Li C, Kumar S, et al. The TGF beta receptor endoglin in systemic sclerosis. Asian Pac J Allergy Immunol 2001;19:275-82.